UBS Group Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $2.20

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target reduced by UBS Group from $5.00 to $2.20 in a research note published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Other analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, Guggenheim dropped their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Down 12.2 %

ZNTL opened at $1.66 on Tuesday. The stock has a market cap of $118.29 million, a PE ratio of -0.67 and a beta of 1.86. Zentalis Pharmaceuticals has a twelve month low of $1.66 and a twelve month high of $18.07. The company has a fifty day moving average of $2.97 and a 200-day moving average of $3.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Verition Fund Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Primecap Management Co. CA boosted its holdings in shares of Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after acquiring an additional 265,690 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after acquiring an additional 399,745 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after acquiring an additional 353,384 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after purchasing an additional 127,868 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.